Development of multidrug resistance (MDR) to conventional and newer generations of anticancer therapeutics is a significant challenge in cancer therapy. MDR is presented clinically as a consequence of many factors that include poor systemic drug delivery efficiency, short residence time, poor permeability in tumor mass and intracellular availability, as well as microenvironmental selection pressures that give rise to resistant phenotype. As such, our innovative strategy to overcome MDR is based on development of combinatorial designed nano-formulation libraries with encapsulated small interference RNA (against mdr-1 and mrp-1 efflux transporter and Bcl-2 and survivin anti-apoptotic genes) and cytotoxic therapeutic agents (paclitaxel and doxorubicin). Our preliminary studies show that this multimodal therapeutic approach has significant potential in the treatment of refractory tumors.
The specific aims of this project are: (1) to synthesize and characterize dextran-based macrostructures with fatty acids, thiol groups, poly(ethylene glycol) (PEG), and epidermal growth factor receptor (EGFR)- targeting peptide for combinatorial self-assembly in aqueous media into nanostructures that can encapsulate siRNA duplexes, paclitaxel, and doxorubicin;(2) high-throughput evaluation of cellular delivery and vesicular stability of siRNA duplexes and drugs, quantitative and qualitative gene silencing efficacy, cytotoxicity and apoptotic activity in wild-type (SK0V3) mdr-1 positive (SKOVSTR) human ovarian adenocarcinoma and wild- type (NIH-H69) and mrp-1 positive (NIH-H69AR) small cell lung adenocarcinoma cells;(3) selection of """"""""hits"""""""" for in vivo evaluation of tumor targeting efficacy, residence, biodistribution profiles, and evaluation of non- compartmental pharmacokinetics in SK0V3TR and NIH-H69AR tumor xenograft models after systemic administration;(4) further refinement of """"""""hits"""""""" and evaluation of in vivo gene silencing efficacy, tumor suppression, and inhibition of metastasis resistant tumor xenograft models after systemic administration of single and combination sIRNA/drug co-therapy;and (5) determination of acute safety profiles by measuring changes in body weight, blood cell counts, liver enzymes, and liver tissue histopathology with single and combination siRNA/drug co-therapy in resistant tumor models. The proposed clinically-translatable strategy holds tremendous promise in the treatment of refractory ovarian and small cell lung cancers, which continue to have very high mortality rates in the United States.

Public Health Relevance

Tumor multidrug resistance (MDR) is a serious challenge in clinical cancer therapy. A multimodal approach that enhances drug delivery efficiency as well as overcomes cellular resistance is necessary to successfully treat MDR in cancer patients. In this study, we will develop a novel class of biocompatible dextran-based polymeric nano-assembled structures for encapsulation and delivery of small interfering RNA that can silence specific genes in resistant cells. and cytotoxic drugs for maximum cell-kill effect.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA151452-04
Application #
8537848
Study Section
Special Emphasis Panel (ZCA1-SRLB-X (M1))
Program Officer
Grodzinski, Piotr
Project Start
2010-09-01
Project End
2015-07-31
Budget Start
2013-08-15
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$386,926
Indirect Cost
$160,897
Name
Northeastern University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Li, Xiaoyang; Seebacher, Nicole A; Garbutt, Cassandra et al. (2018) Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. Cell Death Dis 9:446
Ahmad, Gulzar; Gattacecca, Florence; El Sadda, Rana et al. (2018) Biodistribution and Pharmacokinetic Evaluations of a Novel Taxoid DHA-SBT-1214 in an Oil-in-Water Nanoemulsion Formulation in Naïve and Tumor-Bearing Mice. Pharm Res 35:91
Wang, Jinglu; Garbutt, Cassandra; Ma, Hangzhan et al. (2018) Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer. Gynecol Oncol 150:143-150
Chen, Hua; Shen, Jacson; Choy, Edwin et al. (2018) Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells. Oncotarget 9:13154-13166
Gao, Peng; Seebacher, Nicole A; Hornicek, Francis et al. (2018) Advances in sarcoma gene mutations and therapeutic targets. Cancer Treat Rev 62:98-109
Ma, Hangzhan; Li, Xiaoyang; Wang, Jinglu et al. (2018) Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma. Oncology 95:52-60
Tang, Fan; Choy, Edwin; Tu, Chongqi et al. (2017) Therapeutic applications of histone deacetylase inhibitors in sarcoma. Cancer Treat Rev 59:33-45
Liao, Yunfei; Sassi, Slim; Halvorsen, Stefan et al. (2017) Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Sci Rep 7:43941
Duan, Zhenfeng; Gao, Yan; Shen, Jacson et al. (2017) miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo. Mol Oncol 11:151-166
Chen, Hua; Garbutt, Cassandra C; Spentzos, Dimitrios et al. (2017) Expression and Therapeutic Potential of SOX9 in Chordoma. Clin Cancer Res 23:5176-5186

Showing the most recent 10 out of 64 publications